{"article_id": "BIO_q1_2021.txt", "article": ["net sales for the first quarter of 2021 were $ 726.8 million , which is a 27.1 % increase on a reported basis versus $ 571.6 million in q1 of 2020 .", "on a currency - neutral basis , sales increased 23.4 % .", "the first quarter year - over - year revenue growth was impacted by a tough compare of about $ 10 million revenue carryover to q1 of 2020 related to the december 2019 cyber-attack .", "generally , we are seeing most academic and diagnostic labs now running about 90 % capacity , which is an improvement to what we saw in q4 .", "we estimate that covid - 19 - related sales were about $ 94 million in the quarter .", "sales of the life science group in the first quarter of 2021 were $ 366.5 million compared to $ 227.2 million in q1 of 2020 , which is a 61.3 % increase on a reported basis , and a 56.9 % increase on a currency - neutral basis .", "excluding process media sales , the underlying life science business grew 56.2 % on a currency - neutral basis versus q1 of 2020 .", "sales of the clinical diagnostics group in the first quarter were $ 358.5 million , compared to $ 340.3 million in q1 of 2020 , which is a 5.4 % growth on a reported basis , and a 2.2 % growth on a currency - neutral basis .", "we started to see a recovery of market demand for non-covid business , with diagnostics labs returning to about 90 % of pre-covid levels .", "the reported gross margin for the first quarter of 2021 was 55.1 % on a gaap basis , and compares to 55.5 % in q1 of 2020 .", "amortization related to prior acquisitions recorded in cost of goods sold was $ 4.6 million compared to $ 3.9 million in q1 of 2020 .", "sg&a expenses for q1 of 2021 were $ 225.9 million or 31.1 % of sales compared to $ 193.7 million or 33.9 % in q1 of 2020 .", "the year - over - year sg&a expenses increased mainly due to expenses associated with the restructuring initiative and higher employee - related expenses , and it was offset slightly by a $ 5 million cybersecurity insurance settlement related to the 2019 cyber - attack as well as lower discretionary spend .", "total amortization expense related to acquisitions recorded in sg&a for the quarter was $ 2.4 million versus $ 2 million in q1 of 2020 .", "research and development expense in q1 was $ 73.9 million or 10.2 % of sales compared to $ 49.3 million or 8.6 % in q1 of 2020 .", "q1 operating income was $ 100.9 million or 13.9 % of sales compared to $ 74.4 million or 13 % in q1 of 2020 .", "the change in fair market value of equity securities holdings added $ 1.179 billion of income to the reported results , which is substantially related to holdings of the shares of sartorius ag .", "during the quarter , interest and other income resulted in net other income of $ 16.9 million compared to $ 3.3 million of expense last year .", "q1 of 2021 included $ 19 million of dividend income from sartorius , which was declared this year in q1 .", "the effective tax rate for the quarter was 24.7 % compared to 23.7 % in q1 of 2020 .", "reported net income for the first quarter was $ 977.4 million , and diluted earnings per share were $ 32.38 .", "in cost of goods sold , we have excluded $ 4.6 million of amortization of purchased intangibles , $ 24 million of restructuring - related expenses and a small legal reserve benefit .", "these exclusions moved the gross margin for the first quarter of 2021 to a non-gaap gross margin of 59 % versus 55.9 % in q1 of 2020 .", "non-gaap sg&a in the first quarter of 2021 was 25.4 % versus 33.3 % in q1 of 2020 .", "in sg&a , on a non-gaap basis , we have excluded restructuring - related expenses of $ 34.7 million , legal - related expenses of $ 4.4 million , and amortization of purchased intangibles of $ 2.4 million .", "in r&d , we have excluded $ 16.9 million of restructuring - related expenses .", "the non-gaap r&d expense in q1 was consequently 7.9 % .", "the cumulative sum of these non-gaap adjustments result in moving the quarterly operating margin from 13.9 % on a gaap basis to 25.8 % on a non-gaap basis .", "this non-gaap operating margin compares to a non-gaap operating margin in q1 of 2020 of 13.9 % .", "we have also excluded certain items below the operating line , which are the increasing value of the sartorius equity holdings of $ 1.179 billion , and $ 1.8 million of loss associated with venture investments .", "our non-gaap effective tax rate for the quarter was 23.6 % versus 25.7 % in q1 of 2020 .", "and finally , non-gaap net income for the first quarter of 2021 was $ 157.4 million , or $ 5.21 diluted earnings per share compared to $ 57.6 million and $ 1.91 per share in q1 of 2020 .", "total cash and short - term investments at the end of q1 were $ 1.025 billion , compared to $ 997 million at the end of 2020 .", "during the first quarter , we purchased 89,506 shares of our stock for a total of $ 50 million at an average price of approximately $ 559 per share .", "for the first quarter of 2021 , net cash generated from operations was $ 114 million , which compares to $ 63 million in q1 of 2020 .", "the adjusted ebitda for the fourth quarter of 2021 was $ 232 million or 31.9 % of sales , and excluding the sartorius dividend , was 29.3 % .", "the adjusted ebitda in q1 of 2020 was $ 107.4 million or 18.8 % of sales , which did not include the 2020 sartorius dividend .", "net capital expenditures for the first quarter of 2021 were $ 19.5 million , and depreciation and amortization for the first quarter was $ 32.7 million .", "we began the year with a projection of between 4.5 % and 5 % non-gaap sales growth , and a non-gaap operating margin of between 16 % and 16.5 % .", "even though we continue to be uncertain about the duration and impact of the covid - 19 pandemic , given the results of the first quarter and our current outlook , we are now guiding currency - neutral revenue growth in 2021 to be between 5.5 % and 6 % .", "this includes covid - related sales , which we estimate to be between $ 170 million and $ 180 million versus our prior estimate of about $ 150 million and $ 160 million .", "full year non-gaap gross margin is now projected between 56.5 % and 57 % versus our previous guidance of 56.2 % and 56.5 % .", "and full year non-gaap operating margin to be about 17 % , and full year adjusted ebitda margin to be about 22 % versus previous guidance of 21 % ."], "summary_gold": "compname reports q1 non -gaap earnings per share of $ 5.21 .<q>q1 non -gaap earnings per share $ 5.21 .<q>q1 earnings per share $ 32.38 .<q>q1 sales rose 27.1 percent to $ 726.8 million .<q>for full year 2021 anticipates non-gaap currency - neutral revenue growth of approximately 5.5 to 6.0 percent .", "summary_pred": "generally , we are seeing most academic and diagnostic labs now running about 90 % capacity , which is an improvement to what we saw in q4 .<q>the effective tax rate for the quarter was 24.7 % compared to 23.7 % in q1 of 2020 .<q>reported net income for the first quarter was $ 977.4 million , and diluted earnings per share were $ 32.38 .<q>full year non-gaap gross margin is now projected between 56.5 % and 57 % versus our previous guidance of 56.2 % and 56.5 % .<q>we have also excluded certain items below the operating line , which are the increasing value of the sartorius equity holdings of $ 1.179 billion , and $ 1.8 million of loss associated with venture investments .<q>during the quarter , interest and other income resulted in net other income of $ 16.9 million compared to $ 3.3 million of expense last year .<q>q1 of 2021 included $ 19 million of dividend income from sartorius , which was declared this year in q1 .<q>the adjusted ebitda for the fourth quarter of 2021 was $ 232 million or 31.9 % of sales , and excluding the sartorius dividend , was 29.3 % .<q>the cumulative sum of these non-gaap adjustments result in moving the quarterly operating margin from 13.9 % on a gaap basis to 25.8 % on a non-gaap basis .<q>we estimate that covid - 19 - related sales were about $ 94 million in the quarter .<q>we began the year with a projection of between 4.5 % and 5 % non-gaap sales growth , and a non-gaap operating margin of between 16 % and 16.5 % .<q>on a currency - neutral basis , sales increased 23.4 % .<q>the year - over - year sg&a expenses increased mainly due to expenses associated with the restructuring initiative and higher employee - related expenses , and it was offset slightly by a $ 5 million cybersecurity insurance settlement related to the 2019 cyber - attack as well as lower discretionary spend .<q>the non-gaap r&d expense in q1 was consequently 7.9 % .", "len_article": 43, "len_summary_gold": 5, "len_summary_pred": 14, "len_sent_scores": 43}